Immutep (IMM) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock IMM Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Immutep announces update for TACTI-004 Phase III trialOctober 10 at 9:32 AM | msn.comImmutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung CancerOctober 9 at 11:05 AM | markets.businessinsider.comImmutep Ltd Announces Director’s Interest ChangeOctober 8 at 7:58 PM | msn.comImmutep Director Converts Performance Rights into SharesOctober 8 at 4:46 AM | msn.comASX Stocks That May Be Undervalued In October 2025October 5, 2025 | finance.yahoo.comImmutep Ltd Issues New Shares on ASXOctober 1, 2025 | msn.comAltium And 2 Other High Growth Tech Stocks In AustraliaSeptember 29, 2025 | uk.finance.yahoo.comWe're Not Very Worried About Immutep's (ASX:IMM) Cash Burn RateSeptember 29, 2025 | finance.yahoo.comLooking for a biotech multi-bagger? This could be the one.September 23, 2025 | msn.comImmutep enters reseach collaboration with GW University Cancer CenterSeptember 22, 2025 | msn.comImmutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant EftiSeptember 22, 2025 | markets.businessinsider.comImmutep Collaborates with GW Cancer Center on Efti Trial for Breast CancerSeptember 21, 2025 | tipranks.comImmutep’s Phase II Trial Data on Soft Tissue Sarcoma to be Presented at CTOS 2025September 7, 2025 | tipranks.comImmutep Reports Increased Losses Amid Rising R&D CostsSeptember 3, 2025 | tipranks.comImmutep Limited (IMMP) Receives Positive FDA Feedback on Future Clinical Development of Eftilagimod AlfaAugust 17, 2025 | msn.comImmutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS 1August 6, 2025 | tmcnet.comImmutep Limited: Immutep Quarterly Activities Report Q4 FY25July 30, 2025 | finanznachrichten.deImmutep Advances Oncology Trials with Promising ResultsJuly 30, 2025 | msn.comImmutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025July 28, 2025 | finance.yahoo.comImmutep’s Eftilagimod Alfa Trials to be Showcased at ESMO 2025July 27, 2025 | tipranks.comImmutep Limited (PRRUF) stock price, news, quote & history - Yahoo FinanceJune 30, 2025 | sg.finance.yahoo.comWith 51% institutional ownership, Immutep Limited (ASX:IMM) is a favorite amongst the big gunsJune 24, 2025 | uk.finance.yahoo.comImmutep Limited: Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune DiseasesJune 23, 2025 | finanznachrichten.deImmutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune DiseasesJune 23, 2025 | finance.yahoo.comImmutep ADRs Rise on Trial Results for Non-Small Cell Lung Cancer TreatmentMay 16, 2025 | marketwatch.comImmutep stock soars on promising trial resultsMay 5, 2025 | investing.comImmutep Cancer Treatment Shows High Survival RateMay 5, 2025 | marketwatch.comImmutep Limited: Immutep Quarterly Activities Report Q3 FY25April 30, 2025 | finanznachrichten.deImmutep announces first patient dosed in TACTI-004 Phase III trialMarch 27, 2025 | markets.businessinsider.comHealth Check: Bargain hunters flock to 4D Medical’s discounted raisingMarch 24, 2025 | msn.comImmutep notches upward on first lung cancer patient dosingMarch 24, 2025 | msn.comImmutep announces poster presentation for the TACTI-004 Phase III trialMarch 21, 2025 | markets.businessinsider.comImmutep Ltd (PRRUF) Receives a Buy from Canaccord GenuityMarch 7, 2025 | markets.businessinsider.comWhy Immutep (IMMP) Is Among the Best Australian Stocks to Buy Now?January 27, 2025 | msn.comImmutep announces patient enrollment completed for EFTISARC-NEO Phase II trialJanuary 22, 2025 | markets.businessinsider.comPatient Enrolment Completed for INSIGHT-003January 6, 2025 | finance.yahoo.comImmutep dips as safety test for flagship drug IMP761 shows no adverse effectsDecember 17, 2024 | msn.comImmutep Ltd Reveals Key LAG-3 Binding DiscoveryDecember 16, 2024 | msn.comMolecular insights unlock a targeted approach to cancer immunotherapyDecember 14, 2024 | msn.comASX 300 healthcare stock lifts off on promising new resultsDecember 11, 2024 | msn.comImmutep Ltd Advances Efti in Cancer Treatment TrialsNovember 22, 2024 | markets.businessinsider.comImmutep Limited Passes All AGM ResolutionsNovember 21, 2024 | markets.businessinsider.comImmutep Ltd Sees Increased Stake from Regal FundsNovember 18, 2024 | msn.comAnalysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI) and Immutep Ltd (OtherPRRUF)November 18, 2024 | markets.businessinsider.comImmutep price target raised to $7 from $6 at BairdNovember 17, 2024 | markets.businessinsider.comImmutep Reports Promising Phase II Sarcoma Trial ResultsNovember 16, 2024 | markets.businessinsider.comImmutep Reports Promising Phase II Sarcoma Trial ResultsNovember 16, 2024 | markets.businessinsider.comImmutep’s Promising Lung Cancer Trial ResultsNovember 16, 2024 | markets.businessinsider.comImmutep’s Promising Lung Cancer Trial ResultsNovember 16, 2024 | markets.businessinsider.comImmutep Limited: Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung CancerNovember 15, 2024 | finanznachrichten.de Get Immutep News Delivered to You Automatically Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMM Media Mentions By Week IMM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMM News Sentiment▼0.180.77▲Average Medical News Sentiment IMM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMM Articles This Week▼51▲IMM Articles Average Week Get the Latest News and Ratings for IMM and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Immutep and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies GNS News Today ONC News Today ONT News Today BIO News Today OXB News Today FRX News Today PRTC News Today AVCT News Today FARN News Today TH News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (ASX:IMM) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immutep Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Immutep With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
